Wearable Injectors - Market Insights, Competitive Landscape, and Market Forecast - 2027

Wearable Injectors Market By Type (On-Body Injectors And Off-Body Injectors), By Indication (Oncology, Autoimmune Disease, Diabetes, Cardiovascular Disease, And Others), By End-User (Hospitals & Clinics, Home Care, And Others), and by geography expected to grow at a steady CAGR forecast till 2027 owing to the rising prevalence of various chronic diseases such as cancers, diabetes, cardiovascular, among others and the rising innovations and technological advancement in this arena.

The global wearable injectors market was valued at USD 6,725.58 million in 2021, growing at a CAGR of 12.78% during the forecast period from 2022 to 2027 to reach USD 13,815.56 million by 2027. The wearable injectors market is indorsing optimistic growth primarily owing to the increasing incidences of chronic conditions such as cancer, diabetes, and cardiovascular disorders among others. Further, rising concern over the hazards and limitations related to needle sticks, rising need & demand for patient compliance to treatment, and rising innovations & technological advancement in the device will create a requisite for wearable injectors in the market. In addition, the increasing product launches and approvals, and the rising reimbursement scenarios across the globe will further upsurge the overall growth of the wearable injectors market. Therefore, the market for wearable injectors is estimated to grow at a significant CAGR during the forecast period from 2022 to 2027.

Wearable Injectors Market Dynamics:

According to World Health Organization (WHO) 2022 factsheet, cancer is a leading cause of death worldwide, accounting for nearly 10 million deaths in 2020. The new cases of breast cancer in 2020 was 2.26 million, followed by lung cancer with 2.21 million cases, colon and rectum cancer reported 1.93 million news cases, prostate cancer 1.41 million cases, skin cancer - 1.20 million cases and stomach cancer 1.09 million cases, worldwide.

As per the 10th Edition of the International Diabetes Federation 2021, nearly 537 million adults (20-79 years) were living with diabetes. This number is predicted to rise to 643 million by 2030 and 783 million by 2045.

Thus, the increasing prevalence of chronic diseases will, leads to an increase in demand for wearable injectors as the injectors are used for administering various drugs over an extended period to patients suffering from chronic diseases. Cardiovascular diseases are considered to be the leading cause of death globally. As per the World Health Organization in the year 2021, an estimated 17.9 million people died from cardiovascular disorders in 2019, illustrating 32% of all global deaths. Out of the 17 million premature deaths (under the age of 70 years) due to non-communicable diseases in 2019, 38% of the deaths were caused due to cardiovascular disorders. The mortality rate can be reduced or controlled if the wearable injectors are used at an apt time to administer the drugs to the cardiovascular patients. Thus, leading to an increased demand of wearable injectors, ultimately propelling the overall market growth.

The various strategies adopted by key market players to launch innovative products are further expected to aid the market's growth over the forecast period. For example, in February 2021, Phillips-Medisize, a Molex company and a leader in the design, development, and manufacturing of drug delivery, diagnostic, and MedTech devices, collaborated with Subcuject, a global innovator of proprietary device platforms, to bring to market a game-changing wearable bolus injector.

Therefore, the factors stated above collectively will drive the overall market of wearable injectors during the forecast period from 2022-2027.

However, the preference for alternative drug delivery modes, certain side effects caused due to the nanoparticles of the system, and the high cost of the wearable injectors, among others, can hinder the global wearable injector's market growth.

The COVID-19 pandemic has significantly impacted the market for wearable injectors. The outbreak of the pandemic led to strict social distancing norms, reduced socializing among people, and restrictions on mobility among consumers directed to a drop in wearable injectors usage with consumers finding it hard to visit stores to buy the wearable injectors, thereby decreasing the demand and overall market of wearable injectors in the initial phase of the lockdown. However, the rising demand for wearable injectors for the self-administration of drugs during to pandemic led to an increased demand for wearable injectors. Moreover, with the ease in the supply chain, manufacturing, & lockdown restrictions, and the increasing trend of e-commerce sales for wearable injectors the market of wearable injectors increased at a healthy growth rate. Thus, owing to the above-mentioned factors the wearable injectors business registered a lucrative growth in the other half of the pandemic, and the trend is anticipated to rise in the same manner in the upcoming years.

Wearable Injectors Market Segment Analysis:

Wearable Injectors Market by Type (On-Body Injectors and Off-Body Injectors), Indication (Oncology, Autoimmune Disease, Diabetes, Cardiovascular Disease, and Others), End-User (Hospitals & Clinics, Home Care, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World)
In the therapy segment of the wearable injectors market, the oncology segment tends to hold a significant revenue share in the year 2021. This was primarily owing to the rising incidences of various cancers across the globe.

For instance, according to a 2021 update by the World Health Organization (WHO), the new cancer cases in 2020 were breast cancer with 2.26 million cases, lung cancer is the second most common cancer type with 2.21 million cases followed by colon and rectum cancer with 1.93 million cases, prostate cancer with 1.41 million cases, skin (non-melanoma) cancer with 1.20 million cases, and stomach cancer with 1.09 million cases.

The latest data published by the Canadian Cancer Society estimates that approximately 7% of Canadian males will get lung and bronchus cancer in their lifetime, and approximately 5% will pass away from it, every year.

Further, there are several biologic drugs for oncology, but they necessitate frequent administration and visits to a hospital or specialized clinic, resulting in high costs and patient discomfort. Wearable injectors are gaining popularity among oncology patients because they allow patients to self-administer the drug, improving their lives. Essentially, their ability to deliver anti-tumor agents automatically and safely is a key growth driver for this category.

Recent strategic activities such as product launches in the domain of wearable injectors will also drive market growth. For instance, in August 2021, BD results from a 52-subject human clinical trial with the BD Libertas Wearable Injector were announced. The subcutaneous drug delivery system, currently in the final phases of development, is designed to be ready to use and to deliver drugs such as biologics with viscosities up to 50 cP in 2-5 mL and 5-10 mL configurations.

Thus, the aforesaid factors will in turn drive the oncology segment market in the wearable injectors market, thereby propelling the overall market growth of wearable injectors during the forecast period from 2022 - 2027.

North America is expected to dominate the overall Wearable Injectors Market:

Among all the regions, North America is expected to dominate the global wearable injectors market in the year 2021 and is expected to do the same during the forecast period from 2022-2027. This domination is attributed to the rising prevalence of chronic diseases & lifestyle-related diseases, the presence of sophisticated healthcare infrastructure, presence of key players in the region, among others are the key factors contributing to the wearable injectors market growth in the country and is expected to aid in the growth of the North America wearable injectors devices market.

For instance, as per the data provided by the American Cancer Society, it is estimated that in 2023, nearly 1,958,310 new cancer cases and 609,820 cancer deaths are projected to occur in the United States. This indicates that the incidence and mortality rate associated with cancer are significantly high, which increases the demand for surgical procedures, subsequently boosting the demand for drug delivery devices such as wearable injectors driving the market growth.

Also, according to the American Diabetes Association data published in February 2022, diabetes affects more than 29 million people in North America, with that number expected to rise to 33 million by 2026. The large prevalence of these diseases is expected to drive the growth in demand for wearable injectors in the region.

Furthermore, various strategic initiatives taken by the market players, such as product launches, collaborations, mergers, and acquisitions, are expected to boost the market in North America. For instance, in April 2021, CeQur, a maker of insulin delivery devices based in Marlborough, raised USD 115 million in funding as it launched its wearable insulin injector, CeQur Simplicity.

Therefore, the interplay of the aforementioned factors would provide a conducive growth environment for the North America region in the wearable injectors market.

Wearable Injectors Market Key Players:

Some of the key market players operating in the wearable injectors market include BD, Ypsomed, Amgen Inc., West Pharmaceutical Services, Inc., Stevanato Group, Eitan Medical, United Therapeutic Corporation, Bühler Motor GmbH, Sonceboz, Subcuject Aps, Nemera, SHL Medical AG, Gerresheimer AG, Insulet Corporation, CeQur SA, and others.

Recent Developmental Activities in the Wearable Injectors Market:

• In June 2022, AbbVie received United States Food and Drug Administration (FDA) approval for SKYRIZI (risankizumab-rzaa) as the first and only specific interleukin-23 (IL-23) inhibitor for the treatment of adults with moderately to severely active Crohn's disease (CD). It can be self-administered by subcutaneous injection (SC) with an on-body injector (OBI).
• In February 2022, Enable Injections raised a USD 215 million round to fund work on the subcutaneous drug delivery system enFuse. The device consists of a wearable delivery disc and a system for transferring the drug from its original vessel.
• In February 2020, BD announced that it has completed the human clinical trial of its BD Libertas Wearable Injector with 50 subjects.

Key Takeaways from the Wearable Injectors Market Report Study

• Market size analysis for the current wearable injectors market (2021), and market forecast for 5 years (2022-2027)
• The effect of the COVID-19 pandemic on this market is significant. To capture and analyze suitable indicators, our experts are closely watching the wearable injectors market
• Top key product/services/technology developments, mergers, acquisitions, partnerships, and joint ventures happened over the last 3 years
• Key companies dominating the global wearable injectors market
• Various opportunities are available for the other competitor in the wearable injectors market space
• What are the top-performing segments in 2021? How these segments will perform in 2027.
• Which are the top-performing regions and countries in the current wearable injector's market scenario?
• Which are the regions and countries where companies should have concentrated on opportunities for wearable injector's market growth in the coming future?

Target Audience who can be benefited from this Wearable Injectors Report Study

• Wearable Injectors market providers
• Research organizations and consulting companies
• Wearable Injectors market-related organizations, associations, forums, and other alliances
• Government and corporate offices
• Start-up companies, venture capitalists, and private equity firms
• Distributors and traders dealing in the wearable injectors market
• Various end-users who want to know more about the wearable injectors market and the latest developments in the wearable injectors market

Frequently Asked Questions for the Wearable Injectors Market:

1. What are wearable injectors?

Wearable injectors are delivery systems that adhere to the body to administer larger volumes (more than 2 mL) of drug subcutaneously over an extended period.

2. What is the market for wearable injectors?

The global wearable injectors market was valued at USD 6,725.58 million in 2021, growing at a CAGR of 12.78% during the forecast period from 2022 to 2027 to reach USD 13,815.56 million by 2027.

3. What are the drivers for the wearable injectors market?

The wearable injectors market is witnessing positive market growth owing to the factors such as the increasing incidence of chronic conditions such as cancer, diabetes, and cardiovascular disorders among others, increasing concern over the hazards and limitations related to needlesticks, rising need and demand for patient compliance to treatment, rising innovations and technological advancement in the device, and the surging launches and approvals of different types of wearable injectors in the market.

4. Who are the key players operating in the wearable injectors market?

Some of the key market players operating in the wearable injectors market include BD, Ypsomed, Amgen Inc., West Pharmaceutical Services, Inc., Stevanato Group, Eitan Medical, United Therapeutic Corporation, Bühler Motor GmbH, Sonceboz, Subcuject Aps, Nemera, SHL Medical AG, Gerresheimer AG, Insulet Corporation, CeQur SA, and others.

5. Which region has the highest share in the wearable injectors market?

North America is expected to hold the largest share of the global wearable injectors market. Factors contributing to the growth are the rising prevalence of chronic diseases & lifestyle-related diseases, the presence of sophisticated healthcare infrastructure, the presence of key players in the region, and others that are contributing to the growth of wearable injectors in the North America region.